https://www.yiliao.com/index.php?action=history&feed=atom&title=MAPK_%E4%BF%A1%E5%8F%B7
MAPK 信号 - 版本历史
2026-04-16T09:12:08Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=MAPK_%E4%BF%A1%E5%8F%B7&diff=317996&oldid=prev
223.160.136.79：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-04-14T08:13:33Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>MAPK 信号通路</strong>（Mitogen-Activated Protein Kinase Pathway，丝裂原活化蛋白激酶通路）是真核细胞内最保守、最核心的信号转导系统之一。该通路通过经典的“三级激酶级联”模式——即 <strong>[[MAPKKK]]</strong> (激酶之激酶之激酶) &rarr; <strong>[[MAPKK]]</strong> (激酶之激酶) &rarr; <strong>[[MAPK]]</strong> (激酶)——将细胞外的生长因子、应激及炎症细胞因子信号传递至细胞核。MAPK 通路包含四个主要分支：<strong>[[ERK1/2]]</strong>（调节增殖与分化）、<strong>[[JNK]]</strong> 与 <strong>[[p38]]</strong>（调节应激与凋亡）以及 <strong>[[ERK5]]</strong>。由于该通路在肿瘤细胞的失控性生长、抗药性及代谢重构中扮演关键角色，针对 <strong>[[RAS/RAF/MEK/ERK]]</strong> 轴的靶向药物已成为现代肿瘤精准治疗的基石。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[MAPK 信号]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">MAPK Signaling Pathway · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[MAPK]] 三级级联经典结构模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心组分：ERK, JNK, p38</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">代表蛋白 (ERK2)</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">MAPK1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">HGNC 符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6871</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">UniProt 编号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P28482</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">级联模式</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">MKKK &rarr; MKK &rarr; MK</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键负调节</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[DUSP]] (MKPs)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">主要癌症驱动</th><br />
<td style="padding: 12px; color: #b91c1c;">KRAS / BRAF 突变</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多重分支与精准级联</h2><br />
<br />
<br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
MAPK 通路通过将细胞膜表面的受体酪氨酸激酶（RTK）激活状态转化为细胞核内的转录响应，其核心由四个并行的亚通路组成：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>ERK1/2 经典通路：</strong>由 <strong>[[RAS]]</strong> 启动，激活 <strong>[[RAF]]</strong> (MAPKKK)，随后磷酸化 <strong>[[MEK1/2]]</strong> (MAPKK)，最后激活 <strong>[[ERK1/2]]</strong>。该分支主要介导细胞生长、存活及分化信号。</li><br />
<li style="margin-bottom: 12px;"><strong>JNK 与 p38 应激通路：</strong>主要响应紫外线、氧化应激及炎症因子（如 TNF-alpha）。JNK 主要与凋亡调节及代谢相关，而 p38 则在炎症反应和细胞周期阻滞中发挥核心作用。</li><br />
<li style="margin-bottom: 12px;"><strong>双特异性去磷酸化：</strong>通路活性由 <strong>[[DUSP]]</strong> 家族（MAPK磷酸酶）严格限制。这些磷酸酶能同时去除 MAPK 上的苏氨酸和酪氨酸磷酸化残基，防止信号过度持续。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：突变驱动与肿瘤关联</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">突变位点</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">流行病学特征</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床病理意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[KRAS G12C/D]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">胰腺癌 (90%)、肺腺癌 (30%)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">持续激活上游信号，导致下游 ERK 通路不依赖生长因子激活。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[BRAF V600E]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">黑色素瘤 (50%)、甲状腺癌</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">导致 RAF 单体化激活，对常规反馈抑制具有抵抗力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[MEK 突变]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">获得性耐药常见原因</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">常出现在 BRAF 抑制剂治疗后的继发耐药中。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从单靶点阻断到联合用药</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对 MAPK 通路的过度激活，临床已形成了成熟的靶向干预体系，旨在精准“熄灭”致癌信号：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>RAF-MEK 联合抑制：</strong>对于 <strong>[[BRAF V600E]]</strong> 突变，临床通常联用 BRAF 抑制剂（如威罗非尼）与 MEK 抑制剂（如曲美替尼），以延迟耐药发生并减轻代偿性旁路活化。</li><br />
<li style="margin-bottom: 12px;"><strong>RAS 靶向突破：</strong>随着 <strong>[[Sotorasib]]</strong> 等 KRAS G12C 共价抑制剂的上市，曾经“不可成药”的 MAPK 通路上游靶点已被攻克。</li><br />
<li style="margin-bottom: 12px;"><strong>反馈抑制与垂直联用：</strong>针对 <strong>[[EGFR]]</strong> 的反馈性活化，联合应用上游 RTK 抑制剂与下游 MAPK 抑制剂是克服结直肠癌耐药的核心策略。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #ffffff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155; list-style-type: none;"><br />
<li style="margin-bottom: 8px;"><strong>[[PI3K/AKT 轴]]</strong>：MAPK 通路最重要的并行旁路，两者常发生相互代偿。</li><br />
<li style="margin-bottom: 8px;"><strong>[[支架蛋白]] (Scaffold Proteins)</strong>：如 KSR1，负责将三级级联组分物理性靠近以提高传导效率。</li><br />
<li style="margin-bottom: 8px;"><strong>[[AP-1]] 转录因子</strong>：MAPK 通路的主要下游执行者，控制细胞周期进入。</li><br />
<li style="margin-bottom: 12px;"><strong>[[DUSP]]</strong>：双特异性磷酸酶，是通路的天然“制动器”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[细胞老化]] (Senescence)</strong>：持续的强 MAPK 信号可能诱导致癌基因诱导的衰老（OIS）。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kyriakis JM, Avruch J. (2012).</strong> <em>Mammalian MAPK signal transduction pathways activated by stress and inflammation.</em> <strong>[[Physiological Reviews]]</strong>. [Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该综述全面系统地梳理了 MAPK 各分支在哺乳动物生理与病理中的调控精髓。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Braicu C, et al. (2019).</strong> <em>The role of the MAPK/ERK pathway in cancer, from theory to clinical trials.</em> <strong>[[Genes]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：连接了基础信号转导理论与现代肿瘤靶向药物的临床转化历程。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
肿瘤信号转导生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联通路</td><br />
<td style="padding: 10px 15px; color: #334155;">[[PI3K/AKT]] • [[Wnt/beta-catenin]] • [[Notch 信号]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键分子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[KRAS]] • [[BRAF]] • [[MEK1]] • [[ERK2]] • [[ELK1]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">代表药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Trametinib]] • [[Vemurafenib]] • [[Dabrafenib]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">临床实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Precision Oncology]] • [[Liquid Biopsy]] • [[Targeted Therapy]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.79